You said:Oral SERD giredestrant cuts recurrence risk 30% in early HR positive breast cancer Giredestrant, an experimental oral selective estrogen receptor degrader, reduced the risk of invasive disease recurrence or death by 30% compared with standard hormone therapy in a phase 3 trial of more than 4,100 patients with early-stage, hormone receptor-positive, HER2-negative breast cancer.…